1. 1. Mantovani G, et al. Managing cancer-related anorexia/cachexia. Drugs 2001; 61: 499–514. PubMed
2. 2. Inui A. Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin 2002; 52: 72–91. PubMed
3. 3. Tisdale MJ. Clinical anticachexia treatments. Nutr Clin Pract 2006; 21: 168–74. PubMed
4. 4. Jatoi A. Pharmacologic therapy for the cancer anorexia/weight loss syndrome: a data-driven, practical approach. J Support Oncol 2006; 4: 499–502. PubMed
5. 5. Berenstein EG, Ortiz Z. Megestrol acetate for the treatment of anorexia-cachexia syndrome. Available in The Cochrane Database of Systematic Reviews; Issue 2. Chichester: John Wiley; 2005 (accessed 27/06/08). PubMed
6. 6. Yavuzsen T, et al. Systematic review of the treatment of cancer-associated anorexia and weight loss. J Clin Oncol 2005; 23: 8500–11. PubMed
7. 7. Bossola M, et al. Cancer cachexia: it's time for more clinical trials. Ann Surg Oncol 2007; 14: 276–85. PubMed
8. 8. Loprinzi CL, et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol 1999; 17: 3299–3306. PubMed
9. 9. McMillan DC, et al. A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br J Cancer 1999; 79: 495–500. PubMed
10. 10. Dewey A, et al. Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. Available in The Cochrane Database of Systematic Reviews; Issue 1. Chichester: John Wiley; 2007 (accessed 27/06/08). PubMed
11. 11. Gordon JN, et al. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 2005; 54: 540–5. PubMed
12. 12. Mantovani G, et al. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist 2010; 15: 200–11. PubMed
13. 13. Von Roenn JH, et al. Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med 1994; 121: 393–9. PubMed
14. 14. Oster MH, et al. Megestrol acetate in patients with AIDS and cachexia. Ann Intern Med 1994; 121: 400–408. PubMed
15. 15. Clarick RH, et al. Megestrol acetate treatment of growth failure in children infected with human immunodeficiency virus. Pediatrics 1997; 99: 354–7. PubMed
16. 16. Strawford A, et al. Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss: a randomized controlled trial. JAMA 1999; 281: 1282–90. PubMed
17. 17. Mwamburi DM, et al. Comparing megestrol acetate therapy with oxandrolone therapy for HIV-related weight loss: similar results in 2 months. Clin Infect Dis 2004; 38: 895–902. PubMed
18. 18. Grunfeld C, et al. Oxandrolone in the treatment of HIV-associated weight loss in men: a randomized, double-blind, placebo-controlled study. J Acquir Immune Defic Syndr 2006; 41: 304–14. PubMed
19. 19. Gullett NP, et al. Update on clinical trials of growth factors and anabolic steroids in cachexia and wasting. Am J Clin Nutr 2010; 91 (suppl): 1143S–1147S. PubMed
20. 20. Bossola M, et al. Mechanisms and treatment of anorexia in end-stage renal disease patients on hemodialysis. J Ren Nutr 2009; 19: 2–9. PubMed
21. 21. Yeh S-S, et al. Pharmacological treatment of geriatric cachexia: evidence and safety in perspective. J Am Med Dir Assoc 2007; 8: 363–77. PubMed
22. 22. Bodenner D, et al. A retrospective study of the association between megestrol acetate administration and mortality among nursing home residents with clinically significant weight loss. Am J Geriatr Pharmacother 2007; 5: 137–46. PubMed
23. 23. Yeh S-S, et al. Usage of megestrol acetate in the treatment of anorexia-cachexia syndrome in the elderly. J Nutr Health Aging 2009; 13: 448–54. PubMed
24. 24. Ashitani J, et al. Ghrelin and its therapeutic potential for cachectic patients. Peptides 2009; 30: 1951–6. PubMed
May God bless you!
전성수
|